Please provide your email address to receive an email when new articles are posted on . The Hadassah Self-Visual Acuity Screener demonstrated high reliability, accuracy and alignment with standard ...

Please provide your email address to receive an email when new articles are posted on . Mitch Ibach, OD, of Vance Thompson Vision, and colleagues conducted a phase 2, multicenter, randomized, ...

The Companies plan to file an application with the FDA in the second half of 2025. Topline data were announced from a phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for adults with presbyopia.

BRIMOCHOL™ PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no ...

Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults, marking the first FDA-approved ...

Up to 19% of prevalent dementia cases may be attributable to impaired vision, a cross-sectional analysis suggested. Contrast sensitivity impairment showed the strongest relationship, followed by near ...

“In GA, light is not transduced into electrical signals because of a loss of photoreceptors, which leads to an absolute scotoma (blind spot). 2,3 The PRIMA neurostimulation system replaces the lost ...

New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...